Group 1 - The core viewpoint of the news highlights the performance and valuation of Aiwei Technology, which closed at 25.1 yuan, up 3.63%, with a rolling PE ratio of 70.85, marking a new low in 804 days, and a total market value of 1.707 billion yuan [1] - The average PE ratio for the medical device industry is 55.28, with a median of 38.06, placing Aiwei Technology at the 93rd position in the industry ranking [1] - As of the first quarter of 2025, there are 2 institutions holding shares in Aiwei Technology, with a total of 10.42 thousand shares valued at 0.02 million yuan [1] Group 2 - Aiwei Technology specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - The company holds a total of 259 authorized patents (including 97 domestic invention patents and 18 overseas authorized patents) and has 30 software copyrights, along with various medical device registration certificates [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, a year-on-year increase of 24.63%, with a gross profit margin of 55.59% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which has a current PE ratio of 66.05, significantly higher than the industry average of 53.52 [1][2] - As of the first quarter of 2025, Aiwei Technology reported a revenue of 53.30 million yuan, representing a year-on-year increase of 13.85%, and a net profit of 6.32 million yuan, with a year-on-year growth of 24.63% [1] - The company holds a total of 259 authorized patents, including 97 domestic invention patents and 18 overseas patents, indicating a strong focus on innovation in the medical device sector [1] Group 2 - The total market capitalization of Aiwei Technology is 1.591 billion yuan, ranking it 92nd in the medical device industry based on PE ratio [1][2] - The company specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and consumables [1] - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, suggesting that Aiwei Technology is trading at a premium compared to its peers [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aiwei Technology in the medical device industry, noting its high PE ratio compared to industry averages [1][2] - As of July 7, Aiwei Technology's stock closed at 21.69 yuan, with a rolling PE ratio of 61.22 times and a total market capitalization of 1.475 billion yuan [1] - The average PE ratio for the medical device industry is 51.42 times, with a median of 37.44 times, positioning Aiwei Technology at the 90th rank within the industry [1][2] Group 2 - The company specializes in the research, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - As of December 31, 2024, Aiwei Technology and its subsidiaries hold 259 authorized patents (including 97 domestic invention patents and 18 overseas patents) and 30 software copyrights [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, a year-on-year increase of 24.63%, with a gross profit margin of 55.59% [1]

Core Points - The company has approved a differentiated cash dividend distribution plan at the 2024 annual shareholders' meeting held on May 23, 2025 [1][2] - The cash dividend is set at RMB 0.10 per share, with a total distribution amounting to RMB 6,727,800 (including tax) based on the adjusted share capital [2][3] - The total number of shares eligible for the dividend is 67,278,000 after excluding shares held in the company's repurchase account [2][3] Dividend Distribution Details - The cash dividend will be distributed at a rate of RMB 1.00 for every 10 shares held, with no capital reserve transfer or stock issuance involved [2] - The reference price for the ex-dividend date is calculated as the previous closing price minus the cash dividend, with no change in circulating shares [2][3] - Key dates include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [5] Tax Implications - Individual shareholders holding shares for over one year will not be subject to personal income tax on the dividend, while those holding for one year or less will have tax withheld upon stock transfer [7] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of RMB 0.09 per share [8] - Other corporate shareholders will be responsible for their own tax declarations, receiving a gross dividend of RMB 0.10 per share [9]

第一部分 引言 湖南启元律师事务所（以下简称"本所"）受爱威科技股份有限公司（以 下简称"公司"或"爱威科技"）的委托，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所上市公司回购股份实施细则》（以下简称"《回购细则》"）、 《上海证券交易所股票上市规则》（以下简称"《上市规则》"）等法律、行政 法规、部门规章、其他规范性文件的有关规定以及《爱威科技股份有限公司章程》 （以下简称"《公司章程》"），就公司 2024 年度利润分配所涉及的差异化分 红（以下简称"本次差异化分红"）相关事项，按照中国律师行业公认的业务标 准、道德规范和勤勉尽责精神，出具本法律意见。 湖南启元律师事务所 关于爱威科技股份有限公司差异化分红事项 的法律意见书 ·湖南启元律师事务所· HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：0731-82953778 传真：0731-82953779 网站：http://www.qiyuan.com 二〇二五年六月 湖南启元律师事务所 关 ...

关于爱威科技股份有限公司差异化分红事项 的法律意见书 湖南启元律师事务所 ·湖南启元律师事务所· HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：0731-82953778 传真：0731-82953779 网站：http://www.qiyuan.com 二〇二五年六月 湖南启元律师事务所 关于爱威科技股份有限公司差异化分红事项 的法律意见书 致：爱威科技股份有限公司 在爱威科技保证其为本次差异化分红事项向本所提供的原始文件、副本材料 和影印件上的签字、签章均为真实的，其所作的陈述和说明是完整、真实和有效 的，以及一切足以影响本法律意见的事实和文件均已向本所披露，而无任何隐瞒、 疏漏之处的基础上，本所及本所经办律师遵循审慎性及重要性原则，独立、客观、 公正地对本次差异化分红事项进行了查验和确认。 本所及本所经办律师依据《证券法》、《律师事务所从事证券法律业务管理 办法》和《律师事务所证券法律业务执业规则》等法律法规的规定，及本法律意 见出具日以前已经发生或存在的事实，严格履行法定职责，遵循勤勉尽责和诚实 信用原则，进行了充分的核 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-026 爱威科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025年 5月 23 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定，上市公司回购专用账户中的股份，不享有股东大 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.10元 相关日期 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/11 | 2025/7/14 | 2025/7/ ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which operates in the medical device industry [1][2] - As of July 4, Aiwei Technology's closing price was 21.42 yuan, with a PE ratio of 60.46, significantly higher than the industry average of 51.05 [1][2] - The company's total market capitalization is 1.457 billion yuan, ranking it 91st in the medical device industry based on PE ratio [1][2] Group 2 - For Q1 2025, Aiwei Technology reported a revenue of 53.2953 million yuan, representing a year-on-year increase of 13.85%, and a net profit of 6.321 million yuan, up 24.63% year-on-year [1] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [1] - Aiwei Technology holds a total of 259 authorized patents, including 97 domestic invention patents and 18 overseas patents, along with 30 software copyrights [1]

西部证券股份有限公司 关于爱威科技股份有限公司使用部分暂时闲置募集资金 进行现金管理的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为爱威 科技股份有限公司（以下简称"爱威科技"或"公司"）首次公开发行股票并 在科创板上市的保荐人，根据《上海证券交易所科创板股票上市规则》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》《科创板上市公 司持续监管办法（试行）》等法律、行政法规、部门规章及业务规则，对爱威 科技拟使用部分暂时闲置募集资金进行现金管理的事项进行了认真、审慎的核 查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 5 月 10 日出具的《关于同意爱威科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2021〕1628 号），公司获准向社会首次公开发行股票 1,700 万股， 每股发行价格为 14.71 元，本次发行募集资金总额人民币 250,070,000.00 元，实 际募集资金净额为人民币 209,579,847.53 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召开第五届 董事会第四次会议和第五届监事会第四次会议，审议通过《关于公司使用部分暂 时闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 3,800 万元(含本数)的暂时闲置募集资金进行现金管理，用于购买安全性高、满足保本 要求、流动性好的现金管理产品，该决议有效期自公司董事会审议通过之日起 12 个月内，在上述期限内可以滚动使用。董事会授权董事长在经批准的额度、 投资的产品品种和决议有效期限内决定拟购买的具体产品并签署相关合同文件， 具体执行事项由公司财务部负责组织实施。 一、募集资金基本情况 爱威科技股份有限公司 关于使用部分暂时闲置募集资金 进行现金管理的公告 目前公司尚在实施的募投项目情况如下： 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 5 月 10 日出具的《关于同意爱威科技股份有限公 ...